For example, in mouse models, inflamed MOC1 tumors, which are sensitive to ICB treatment, exhibit strong responses to combined STING agonist and ICB treatment, resulting in protective immunity; in contrast, immune-cold MOC2 tumors fail to respond to the same regimen [18], indicating an impaired DNA sensing pathway in these immunotherapy-resistant cancer cells. The gene discussed is STING1; the disease is cancer.